[go: up one dir, main page]

CL2023001860A1 - Composiciones y métodos para reducir hla-a en una célula - Google Patents

Composiciones y métodos para reducir hla-a en una célula

Info

Publication number
CL2023001860A1
CL2023001860A1 CL2023001860A CL2023001860A CL2023001860A1 CL 2023001860 A1 CL2023001860 A1 CL 2023001860A1 CL 2023001860 A CL2023001860 A CL 2023001860A CL 2023001860 A CL2023001860 A CL 2023001860A CL 2023001860 A1 CL2023001860 A1 CL 2023001860A1
Authority
CL
Chile
Prior art keywords
cell
compositions
methods
hla
reducing
Prior art date
Application number
CL2023001860A
Other languages
English (en)
Inventor
Sridhar Srijani
Zhang Yong
Goel Surbhi
Michael Lescarbeau Reynald
Andrew Murray Bradley
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of CL2023001860A1 publication Critical patent/CL2023001860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para reducir la expresión de la proteína HLA-A en una célula que comprende HLA-A modificado genéticamente para su uso, por ejemplo, en terapias de transferencia de células adoptivas.
CL2023001860A 2020-12-23 2023-06-20 Composiciones y métodos para reducir hla-a en una célula CL2023001860A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063130095P 2020-12-23 2020-12-23
US202163250996P 2021-09-30 2021-09-30
US202163254970P 2021-10-12 2021-10-12
US202163288492P 2021-12-10 2021-12-10

Publications (1)

Publication Number Publication Date
CL2023001860A1 true CL2023001860A1 (es) 2024-02-09

Family

ID=81212453

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023001860A CL2023001860A1 (es) 2020-12-23 2023-06-20 Composiciones y métodos para reducir hla-a en una célula
CL2023003086A CL2023003086A1 (es) 2020-12-23 2023-10-17 Composiciones y métodos para reducir los hla-a en una célula

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023003086A CL2023003086A1 (es) 2020-12-23 2023-10-17 Composiciones y métodos para reducir los hla-a en una célula

Country Status (13)

Country Link
US (1) US20240024478A1 (es)
EP (1) EP4267724A2 (es)
JP (1) JP2024500858A (es)
KR (1) KR20230124664A (es)
AU (1) AU2021409732A1 (es)
CA (1) CA3206284A1 (es)
CL (2) CL2023001860A1 (es)
CO (1) CO2023009612A2 (es)
CR (1) CR20230320A (es)
IL (1) IL303971A (es)
MX (1) MX2023007466A (es)
TW (1) TW202239959A (es)
WO (1) WO2022140586A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4599046A1 (en) * 2022-10-05 2025-08-13 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202521564A (zh) 2023-08-14 2025-06-01 美商英特利亞醫療公司 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
TW202515992A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對轉形生長因子β受體２型（ＴＧＦβＲ２）進行基因修飾之組合物及方法
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對ｃｄ７０進行基因修飾之組合物及方法
WO2025049481A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods of editing an hla-a gene in vitro
WO2025049432A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
AU2522095A (en) 1994-05-19 1995-12-18 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
EP2526199A4 (en) 2010-01-22 2013-08-07 Scripps Research Inst PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK3553174T3 (da) 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016141224A1 (en) 2015-03-03 2016-09-09 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
JP7245651B2 (ja) 2016-03-30 2023-03-24 インテリア セラピューティクス，インコーポレイテッド Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
TWI835719B (zh) 2016-12-08 2024-03-21 美商英特利亞醫療公司 經修飾之嚮導rna
WO2018208837A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
AR113031A1 (es) 2017-09-29 2020-01-15 Intellia Therapeutics Inc Composiciones de nanopartículas lipídicas (lnp) que comprende arn
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
WO2019147805A2 (en) 2018-01-26 2019-08-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatory t cells targeted with chimeric antigen receptors
SG11202007563XA (en) * 2018-02-16 2020-09-29 Univ Kyoto Method for producing low-antigenic cell
CN118325839A (zh) 2018-03-27 2024-07-12 宾夕法尼亚大学董事会 具有增强功能的修饰的免疫细胞及其筛选方法
CA3102950A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA3116555A1 (en) 2018-10-15 2020-04-23 University Of Massachusetts Programmable dna base editing by nme2cas9-deaminase fusion proteins
SG11202103571XA (en) 2018-10-16 2021-05-28 Intellia Therapeutics Inc Compositions and methods for immunotherapy
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
EP4143304A2 (en) * 2020-04-28 2023-03-08 Intellia Therapeutics, Inc. Methods of in vitro cell delivery

Also Published As

Publication number Publication date
CL2023003086A1 (es) 2024-05-03
CR20230320A (es) 2023-10-23
CO2023009612A2 (es) 2023-08-09
WO2022140586A2 (en) 2022-06-30
TW202239959A (zh) 2022-10-16
JP2024500858A (ja) 2024-01-10
CA3206284A1 (en) 2022-06-30
WO2022140586A3 (en) 2022-08-04
IL303971A (en) 2023-08-01
KR20230124664A (ko) 2023-08-25
MX2023007466A (es) 2023-08-18
US20240024478A1 (en) 2024-01-25
EP4267724A2 (en) 2023-11-01
AU2021409732A1 (en) 2023-07-20
AU2021409732A9 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
CL2023001860A1 (es) Composiciones y métodos para reducir hla-a en una célula
CR20230303A (es) Composiciones y métodos para reducir el mhc de clase ii en una célula
CL2023001855A1 (es) Composiciones y métodos para modificar genéticamente ciita en una célula
MX2019010196A (es) Composiciones y métodos para la inhibición de proteínas específicas del linaje.
MX2022000553A (es) Modificación de células efectoras inmunitarias y uso de las mismas.
MX2021013766A (es) Restos de separacion y metodos de uso de los mismos.
MX2022006725A (es) Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
BR112023024434A2 (pt) Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
MX2022000016A (es) Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
CL2020000734A1 (es) Expansión y uso de fracciones de células nk ampliadas.
CO2021002386A2 (es) Métodos para la normalización del metabolismo de aminoácidos
CO2024001133A2 (es) Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería
MX2024001443A (es) Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
CO2021016797A2 (es) Composiciones de virus adenoasociadas para la transferencia del gen arsa y métodos de uso de las mismas
CO2025006500A2 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas
CO2024006751A2 (es) Composiciones moduladoras de complemento del factor b y métodos de uso de estas
CO2025000273A2 (es) Composiciones y métodos para reducir mhc de clase i en una célula
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
MX2024002390A (es) Metodos para generar celulas inmunitarias primarias.
BR112021017057A2 (pt) Células, composições e métodos para intensificar a função imune
MX2023011672A (es) Composicion que comprende una microalga eucariota o un extracto de esta para su uso en el tratamiento de una enfermedad viral.